Beam Therapeutics Inc. (BEAM) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 29.49 |
| Open | 29.56 |
| Day High | 30 |
| Day Low | 28.72 |
| 52-Week High | 36.44 |
| 52-Week Low | 15.6 |
| Volume | 1.34M |
| Average Volume | 2.1M |
| Market Cap | 3.04B |
| PE | -60.27 |
| EPS | -0.49 |
| Moving Average 50 Days | 29.36 |
| Moving Average 200 Days | 26.56 |
| Change | 0.04 |
Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)
GlobeNewswire Inc.
Feb 24, 2026 12:01 PM GMT
New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026 Updated Phase 1/2 Data and Next Steps for Pivotal Development for BEAM-302 in Alpha
Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street
GlobeNewswire Inc.
Feb 24, 2026 12:00 PM GMT
$100 Million Funded at Close with up to an Additional $400 Million Available Under Facility with Seven-Year Term Financing Bolsters Balance Sheet with Long-term, Non-dilutive Capital to Support Anticipated Launch of Risto-cel in Sickle Cell Disease (
Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program
GlobeNewswire Inc.
Feb 23, 2026 9:00 PM GMT
CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will announce its fourth quarter and fu